Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

NCT03697551 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Recruitment challenges and not due to safety concerns.

Conditions

Breast Cancer

Interventions

DRUG: Satoreotide trizoxetan

Sponsor

Ipsen